Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
•
Systemic lupus erythematosus
•
Cyclophosphamide
•
General Rheumatology
•
Infectious Disease
•
Tuberculosis
•
Latent Tuberculosis
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
Related Questions
How do you approach the management of digital ischemia in a critically ill patient with infection, but no evidence of active rheumatologic disease?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
How long do you recommend that a patient wear a mask when resuming biologic infusions following a recent upper respiratory infection?
How do you counsel patients who experience diarrhea from mycophenolate mofetil (Cellcept)?
How would you approach management of a patient with mixed cryoglobulinemic vasculitis with predominant skin involvement and no major organ involvement?
For patients with SLE, is there an ANC level for which you would hold or adjust hydroxychloroquine in an asymptomatic patient?
How would you approach management of nodular scleritis in the setting of suspected GCA?
Is there a risk of hepatitis C activation with rituximab in a patient who has a history of HCV treated with antivirals and who is in sustained viral response?